For obese people with a type of heart failure where the heart pumps normally but is stiff, semaglutide helps them feel less short of breath, move easier, and reduces heart inflammation.
Claim Context
Semaglutide 2.4 mg significantly improves cardiac function and reduces symptoms in adults with obesity and heart failure with preserved ejection fraction (HFpEF), as demonstrated by improvements in physical limitations, inflammation, and cardiac remodeling in the STEP-HFpEF trials.
“STEP-HFpEF studies show that 2.4 mg of subcutaneous semaglutide (Wegovy®) improved cardiac remodeling, reduced cardiovascular symptoms and inflammation, and decreased physical limitations.”
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
The pooled effect of semaglutide on HFpEF outcomes across all RCTs.
A systematic review and meta-analysis of all RCTs of semaglutide 2.4 mg in adults with obesity (BMI ≥30 kg/m²) and HFpEF (LVEF ≥50%, elevated NT-proBNP), pooling changes in 6-minute walk distance, NT-proBNP, and echocardiographic parameters, including at least 3 trials with >1000 total participants.
Causal effect of semaglutide 2.4 mg on improving functional capacity and cardiac structure in HFpEF.
A double-blind, placebo-controlled RCT of 500 adults with obesity (BMI ≥30 kg/m²) and HFpEF (LVEF ≥50%, NT-proBNP >125 pg/mL), randomized to semaglutide 2.4 mg weekly or placebo for 52 weeks, with primary outcome: change in 6-minute walk distance and left ventricular mass index by cardiac MRI.
Real-world impact of semaglutide on hospitalization rates and mortality in obese HFpEF patients.
A prospective cohort study of 3000 adults with obesity and HFpEF, comparing rates of heart failure hospitalization and all-cause mortality over 3 years between those prescribed semaglutide 2.4 mg and those on standard care.
Association between semaglutide use and reduced biomarkers of cardiac inflammation in HFpEF.
A matched case-control study of 200 adults with HFpEF and obesity who had a >30% reduction in high-sensitivity CRP after 6 months of semaglutide vs. 400 matched controls with no reduction, assessing baseline and follow-up biomarkers.
Prevalence of improved functional status among semaglutide users with HFpEF at a single time point.
A cross-sectional survey of 1000 adults with obesity and HFpEF, assessing current use of semaglutide and self-reported functional status (NYHA class) and physical activity levels.